YAP1 and non-small cell lung carcinoma: Our IHC experiments indicated that EGFR-mutated lung cancers were associated with higher YAP1 activation, thus YAP1-targeted therapy may potentiate the cytotoxicity of erlotinib (tyrosine kinase inhibitor targeting EGFR) in EGFR-mutated NSCLC cells.